BlueSky

BlueSky Immunotherapies is a clinical-stage biotechnology company based in Vienna, Austria, dedicated to developing innovative immunotherapies for cancer and viral infections. The company's core technology is the proprietary delNS1 platform, which utilizes a replication-deficient influenza virus lacking the non-structural protein 1 (NS1) to trigger a robust interferon-mediated immune response. This platform is designed to overcome the immune-suppressive environment of tumors and induce potent, targeted T-cell activity. BlueSky's lead program, BSI01, is currently in clinical development for HPV-positive malignancies, while other candidates target solid tumors and infectious diseases like COVID-19. By combining viral vector technology with potent immune stimulation, the company aims to provide effective treatments for patients with limited options.